Novo Nordisk A/S said it will reduce the US list price (wholesale acquisition cost) of its semaglutide medicines Wegovy, Ozempic and Rybelsus to $675 per month effective January 1, 2027. The company said this represents an approximately 50% reduction for Wegovy and a 35% reduction for Ozempic versus current list prices, and applies to all doses of the products. Novo Nordisk added that the list-price changes will not affect its direct-to-patient, self-pay prices, and cited ongoing access initiatives including savings offers, NovoCare Pharmacy self-pay options and select telehealth relationships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.